Project Grant R21CA309357
Award Date 9/3/26
Completion Date 8/31/28
Dollars Obligated $440K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cambridge, MA 02142, USA
Similar Awards
- The National Cancer Institute awarded The Broad Institute, Inc. $694,642 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop live-cell RNA sequencing with single-cell resolution. The project addresses a fundamental limitation in molecular omics measurement: current approaches require cell destruction through lysis, extraction, or fixation to detect molecular contents at high multiplexity, preventing serial measurement of living cells to monitor dynamic processes...
- The National Cancer Institute awarded The Broad Institute, Inc., doing business as Broad Institute of MIT and Harvard, $245,297 on July 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop chimeric molecules that trigger generation of neoantigens from proteins dysregulated in infectious disease and cancer. The molecules will be formed by joining clinical-grade protein binders with reactive groups to generate neoantigens that recruit immune system...
- The National Cancer Institute awarded The Broad Institute, Inc. $651,409 under the Cancer Treatment Research program (CFDA 93.395) on July 15, 2026, to probe cereblon allostery with small molecules as a novel approach to targeted protein degradation for cancer therapy. The research examines how allosteric binding at a newly discovered site on cereblon—an E3 ligase substrate adapter targeted by thalidomide derivatives—can modulate protein recruitment and degradation independently or...
- The National Cancer Institute awarded The Regents of the University of California, San Francisco $680,597 on April 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to conduct genome-wide in vivo CRISPR screens in human T cells identifying G protein-coupled receptor pathway targets to enhance CAR-T therapies for solid tumors. The work develops and applies a novel screening platform enabling large-scale genetic screens in human CD4+ and CD8+ T cells within tumor xenografts. Prior...
- Federal Grant Award Summary Seattle Children's Research Institute received a $470,759 Project Grant from the National Cancer Institute (Cancer Treatment Research program, CFDA 93.395) effective September 1, 2025 through August 31, 2027. The award supports development of an innovative CAR-T (Chimeric Antigen Receptor T-cell) immunotherapy platform designed to overcome T-cell exhaustion in solid tumor treatment, specifically targeting hepatocellular carcinoma patients. The research deliverables...
- The National Cancer Institute awarded $164,190 to the University of Pennsylvania on January 15, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support identification of genes that limit CAR T persistence in solid tumors. Work runs through July 31, 2029, and is performed in Philadelphia, Pennsylvania. The project conducts genome-wide in vivo CRISPR screening of human CAR T cell persistence in solid tumor microenvironments. Prior work identified USP22 and ATXN7L3—components of...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded $424,256 to The General Hospital Corporation (Massachusetts General Hospital, Research Management Division) on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop a computational framework for optimal immune monitoring during cancer treatment. The project constructs compartmental models connecting tissue-level lymphocyte dynamics to blood count data,...
- The National Cancer Institute awarded Emory University $100,228 under the Cancer Research Manpower program (CFDA 93.398) on December 1, 2026, to develop a high-throughput force assay for screening chimeric antigen receptor T cell (CAR T) function. The research introduces a novel assay using DNA-based force probes combined with CAS12A enzymatic amplification to quantify piconewton-level forces exerted by CAR T cells via standard plate reader formats. Work includes investigation of how...
- The National Cancer Institute awarded The Johns Hopkins University $387,178 on August 10, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop lipid nanoparticle-based immunotherapy strategies for in-situ generation of dual T cell receptor/chimeric antigen receptor T cells targeting cancer. The award funds research to address the barrier of scalable systems for delivering genetic material to CD4+ T cells. The project leverages a high-throughput mRNA lipid...
- Federal Grant Award Summary Massachusetts Institute of Technology received a $414,803 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded on July 18, 2025, with completion targeted for June 30, 2027. The research focuses on directed evolution of T cell receptors (TCRs) with improved antigen sensitivity to enhance the efficacy and safety of TCR-T cell immunotherapies for cancer treatment. The project will implement high-throughput...